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Percutaneous transluminal coronary
angioplasty
A review of the literature
J. Z. PRZYBOJEWSKI, H. F. H. WElCH
Atherosclerosis is accepted as being a most important disease
process which gives rise to varying clinical presentations
depending upon the part of the vascular system most affected.
Thus, involvement of the head and neck vessels, as well as the
cerebral arteries, can result in a cerebrovascular accident of
varying intensity; abdominal aortic involvement often terminates
in aneurysm formation with its sequelae; mesenteric artery
involvement presents with gastro-intestinal symptoms, such as
'mesenteric angina'; renal artery disease, particularly at the
origins from the abdominal aorta, can express itself in the form of
hypertension and varying degrees of renal decompensation;
involvement of the lower limb vasculature classically presents
with interminent claudication or 'peripheral vascular disease';
and coronary artery atherosclerosis results in the spectrum of
ischaemic heart disease (IHD) as represented by the anginal
syndromes and acute myocardial infarction. Symptomatic relief,
particularly with the disease process involving the coronary
arteries and peripheral vascular disease, was achieved by the
classic operations employing some form of 'bypass' of the
obstructed artery segment. Thus, such palliative procedures as
aorto-iliac, iliofemoral and aortocoronary bypass were introduced
as part of the surgical management of these common clinical
expressions ofatherosclerosis. These operations often resulted in
a dramatic amelioration or actual disappearance ofthe debilitating
symptoms of interminent claudication and angina pectoris,
albeit only temporarily.
A revolutionary non-invasive or non-operative approach to
atherosclerotic obstruction was first introduced on 16 January
1964 by Doner and Judkins. 1 These pioneers described the
technique of 'transluminal recanalization' of peripheral lower
limb arteries employing a Teflon dilatation catheter (Cook Inc.)
inserted percutaneously into the contralateral femoral artery by
the Seldinger technique. This procedure soon became known as
'transluminal angioplasty'. Nevertheless, this intervention
resulted in frequent thrombotic and haemorrhagic complications
which led Andreas Griintzig, a Swiss radiologist working in
Zurich, to design and introduce, in 1974, a unique double-lumen
polyvinyl balloon catheter with non-elastic properties.2,] This
modification made for a far more successful procedure:06
Consequent upon this successful technical modification for use
in peripheral vascular disease, Griintzig, in 1976, developed a
much smaller balloon dilatation catheter for use in coronary
artery disease. 7 Further extensive research workHo utilizing
surgically created .coronary artery obstruction in canine and
human cadaver hearts, as well as intra-operative experimentation
during coronary artery bypass surgery, led Griintzig to perform
the first successful human percutaneous transluminal coronary
angioplasty (PTCA) in Zurich on 16 September 1977. 11 He then
continued to carry out this procedure in a large series of patients
in Switzerland12 prior to its employment in the USAin 1978. 13- 16
The purpose of this article is to review PTCA, which can be
considered to be a truly revolutionary and fairly simple non-
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invasive form of intervention. 17-20 Funhermore, the 'epidemic'
of IHD in the RSA calls for the employment of this technique,
which has already been carried out in a few t~aching hospitals in
this country. Very recently, modified balloon dilatation catheters
have been used percutaneously in the non-operative transluminal
correction of congenital coarctation of the aorta in infants and
children,2H] congenital pulmonary valve stenosis ('valvulo-
plasty'),24,25 and hypoplasia and stenosis of the pulmonary
arteries. 26,27 It has also been employed for PTC.'\ and for the
simultaneous occlusion ofcoronary-bronchial artery anastomosis
using a detachable balloon.28
Equipment
Cine angiographic and video component
Highly sophisticated cardiac catheterization equipment has to
be available before any anempt is made to carry out PTCA.29-]I
The fact that superb quality coronary cine angiograms are
produced by a catheterization laboratory is not necessarily
indicative of suitability to carry out PTCA, since one of the most
essential components of the apparatus, a high-resolution video
imaging system, is often lacking in laboratories performing
routine cardiac catheterization and selective coronary cine
angiography. 32 Facilities should be available for obtaining
cranial and caudal angulations in addition to the more routine
lateral and oblique projections. This can be achieved by a C-arm
cine angiographic system. The ideal cine angiographic apparatus
appears to be a biplane C-arm,32 and some centres even utilize a
biplane isocentric set-up.33 For proper visualization of the
obstructive coronary lesions magnification with 12,5 cm or 15 cm
image intensifiers, as opposed to the 22,5 cm or 25 cm image
intensifiers employed for routine cardiac cine angiography, is
mandatory. With increasing magnification resolution of the
image usually deteriorates but this is counteracted by using a
caesium iodide tube. Electronic magnification increases the
radiation dose and thus increases the danger of radiation to the
operators, technical and nursing staff, as well as to the patient.
Prolonged fluoroscopy is often inevitable in difficult PTCA
cases, but this can be diminished by the availability of a
sophisticated video imaging system. The quality of the video
component is just as important as that of the cine angiognl.phic
one, since correct placement of the dilatation balloon catheter
over the lesion is crucial as is accurate visualization on replay to
determine whether dilatation has been angiographically
successful.
Catheter component
This is a coaxial catheter system and basically consists of two
catheters - the guiding catheter and the dilatation catheter (also
sometimes referred to as the 'balloon catheter' or 'balloon
dilatation catheter'). The guiding catheters are radiopaque and
Teflon-coated and have an external diameter of French 8 - 9.
They have a greater internal diameter when compared with the
standard coronary angiographic catheters and possess Amplatz
or Judkins curves of varying size. In addition, these guiding
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catheter curves can either be 'in-plane' or 'out-of-plane' with
respect to the main shaft of the catheter. This allows for greater
flexibility as regards the aortic arch configuration and location of
the coronary artery ostium. There are several guiding catheters
available such as the Griintzig Dilaca manufactured by Schneider
Medintag AG; the Myler femoral guiding catheter; USCl
Griintzig Dilaca catheters; the Simpson-Robert Vascular
Dilatation System (Advanced Catheter Systems Inc.); and
Stertzer brachial guiding catheters.
The Teflon-eoated dilatation catheters are much more intricate
and smaller, having an external diameter of French 4 - 4,5, since
they have to be passed through the guiding catheters. A vital
component of the dilatation catheter is the balloon, which is
manufactured either from polyvinyl chloride or irradiated
polyolefin. These balloons come in lengths varying between 1,2
and 2,0 cm, the proximal and distal ends being delineated by
radiopaque markers sometimes made of gold. The balloons are
also obtainable with a post-inflation diameter varying between
2,0 and 3,7 mm. An important characteristic of the balloon is its
ability to enlarge to a fixed diameter, thus diminishing the
possibility ofthe transmission ofexcessively high and dangerous
pressure to the coronary artery wall. The dilatation catheter has a
double lumen: one lumen is positioned at the tip of the catheter
to allow for passage of a guidewire and measurement of
intracoronary pressure and injection ofcontrast media; the other
lumen communicates with the balloon to permit the injection of
diluted contrast medium for inflation or deflation. The original
dilatation catheter employed by Griintzig12 (Schneider) had a
soft 5 mm long wire fixed to the distal end of the balloon so as to
avoid any possible injury to the coronary artery wall as well as to
help direct the catheter. Nevertheless, this guidewire was not
'steerable' in the strict sense of the term. During the last year
'steerable' guidewires which are Teflon-coated and have flexible
tips have been introduced,34,35 and according to Griintzig
(personal communication) this innovation has increased the
'primary success rate' ofPTCA.36 These steerable guidewires are
not connected to the dilatation catheter and can, on account of
their manufacturing design, be directed from the proximal
operator-end. A unique feature of these guidewires is that their
stiffness diminishes gradually towards the distal tip. Some of
these are gold-coated over the distal few centimetres to improve
radiopacity.
The remainder of the catheter component to be considered is
the mode of inflation and deflation of the balloon attached to the
dilatation catheter. In Griintzig'sl2 initial description of the
method a 'calibrated pressure pump' (Schneider) was utilized to
inject a saline/contrast medium mixture in a ratio which varied
from 50:50 to as high as 70:30. Some workers employ a hand-
held device regulated by a pressure dial. 34,35,37 Not long ago the
Dorros spring pressurizer38 was introduced, which is an ingenious
device utilizing a calibrated spring controlled by the rotation ofa
screw. Other workers have recommended the use of a two-way
stopcock positioned between the hand-held inflating syringe and
balloon port of the dilatation catheter which allows for constant
pressure application and relieves the operator. 39
A most recent innovation has been the introduction of a
double dilatation catheter allowing for the simultaneous correc-
tion of serial coronary stenoses. This new addition to the
equipment range employed in PTCA will broaden the indications
for this procedure, as well as curtail the time taken to perform it.
Technique
Assessment of coronary cine angiograms
Prior to any attempt at PTCA the selective coronary cine
angiograms obtained during previous cardiac catheterization
should have been meticulously reviewed by the cardiological
unit to assess the feasibility or otherwise of the procedure
(parameters determining this decision will be discussed later).
These cine angiograms must then be critically scrutinized in
consultation with the cardiothoracic surgical team so as to obtain
a consensus as to whether the procedure is preferable to the more
conventional aortocoronary bypass graft operation. Furthermore,
the patient's coronary anatomy must lend itself to such a bypass
procedure.40- 42 This combined consultation is especially im-
portant to ensure the surgical team's preparedness and willingness
to embark on emergency or elective aortocoronary bypass.
surgery in the event of complications arising from PTCA. It is
most unusual for PTCA to be carried out at the same sitting as
routine selective coronary cine angiography, since the suitability
or otherwise of this procedure in a particular patient cannot be
predetermined.43-45 Furthermore, adequate evaluation qf the
coronary cine angiograms is not possible in the time available;
assessment then must be based on videotape replay recordings
rather than on processed film; the patient is not prepared fQr the
procedure; and the surgical team is not always available on
emergency standby. The cardiologists responsible for carrying
out PTCA must measure the dimensions of the coronary artery
stenosis and proximal and distal parts ofthe coronary artery from
selective coronary cine angiograms in order to know what size of
balloon dilatation catheter to utilize. At Tygerberg Hospital
some cut films are also taken ofthe 35 mm cine-angiographic still
frames in several projections and these plates are displayed on
the viewing screen in the cardiac catheterization laboratory
during PTCA.
Medication prior to PTCA
Fully informed consent is mandatory and the patient must
agree to aortocoronary bypass surgery or any other surgical
intervention in case of failure. Since one of the most important
indications for PTCA is angina pectoris unresponsive to maximal
drug therapy, the patients are usually taking a combination of
oral long-acting nitrates, calcium antagonists and R-blocking
drugs,,6- 49 The nitrates and calcium antagonists are continued
for their anti-vasospastic activity but some workers discontinue
the R-blocker on the grounds that this drug can potentiate
coronary vasospasm during PTCA. At Tygerberg Hospital B-
blockers are continued in cases ofunstable angina pectoris, since
these patients are likely to develop acute myocardial infarction
on withdrawal, especially if this is rapid..There is much variation
in drug protocol at various institutions but most agree that some
form of antiplatelet therapy is necessary on account of the
exposure ofa 'raw area' after PTCA. Therefore, a combination of
dipyridamole (Persantin) 100 - 200 mg 3 times daily and aspirin
75 - 100 mg daily is administered I - 3 days prior to PTC1\.. In
Griintzig's original description of the procedure aspirin was
given in a dose of I g daily for 3 days starting 1 day before PTCA.
Most workers appear to administer aspirin in these high doses
despite the fact that it has been demonstrated that this dose
decreases prostacyclin (PGI2) synthesis (anti-vasospastic) and
increases the activity of thromboxane A2 (TXA2) (pro-vaso-
spastic). Because of these considerations we at Tygerberg
Hospital have opted to give a small dose ofaspirin in the form of
'Junior Aspirin' 75 mg (one-quarter the normal 300 mg tablet)
daily, starting 2 days before PTCA, in addition to dipyridamole
lOO mg 3 times daily. Some workers even begin heparin infusion
a few days prior to PTCA. When the patient is in the cardiac
catheterization laboratory a bolus of 10000 units heparin sodium
is administered via an infusion line in an arm vein and further
boluses of 5000 units every 35 minutes during the procedure.
Low-molecular-weight dextran 40 (Rheomacrodex) is then
infused at a rate of 250 ml in the first hour and a further 250 ml
over the succeeding 4 hours.
Use of a prophylactic temporary pacemaker
A temporary bipolar pacemaker electrode is inserted
percutaneously in the contralateral femoral vein and positioned
